Novo Nordisk A/S (NVO)
40.52
-0.41
(-1.00%)
USD |
NYSE |
Apr 17, 16:00
40.64
+0.12
(+0.30%)
After-Hours: 20:00
Novo Nordisk SG&A Expense (Quarterly) : 2.718B for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Evaxion AS | 1.491M |
| Ascendis Pharma A/S | 158.13M |
| Viking Therapeutics, Inc. | 11.28M |
| DBV Technologies SA | 12.79M |
| Cellectis SA | 4.798M |